By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Mooslackengasse 17

Vienna    A-1190  Austria
Phone: 43-664-5495688 Fax: 43-1-230-603046


Company News
f-Star Announces Publication In Molecular Therapy Of Preclinical Data Evaluating Its Lead Compound FS102 For The Treatment Of HER2-Positive Cancers 10/5/2015 9:54:16 AM
f-Star Approves Novartis AG (NVS)'s Cosentyx for Painful Skin Disease 1/21/2015 4:17:56 PM
Bristol-Myers Squibb Company (BMY) Forges $475 Million Pact For Rights To f-Star's Cancer Drug 10/28/2014 5:57:19 AM
f-Star Announces Formation of New Asset-Centric Vehicle, F-Star Alpha Ltd, With €9.4 Million Series A Investment 10/23/2013 10:13:22 AM
f-Star, Merck Serono Sign $708 Million Deal for Antibody-Derived Therapeutics 9/7/2011 8:02:05 AM
f-Star Raises Roughly $22 Million in New Financing Led by SR One 4/13/2011 7:05:39 AM
f-Star and Boehringer Ingelheim Corporation to Collaborate in Discovery and Development of Therapeutic Antibodies; Deal Could be Worth Over 1.2 Billion Euros 11/22/2010 6:37:11 AM
Antibody Engineering Company f-Star Buys Back Royalty Obligations 3/28/2008 6:40:49 AM
Antibody Engineering Company f-Star Opens Second Research Site in Cambridge, UK 3/12/2008 9:32:18 AM
Antibody Engineering Company f-Star Appoints Three Pioneers in Antibody Engineering and Development to its Newly Established Scientific Advisory Board 12/12/2007 8:17:18 AM